Valuation: Penumbra, Inc.

Market Cap 12.59B 11.06B 10.33B 9.48B 17.74B 1,206B 18.18B 122B 47.89B 597B 47.27B 46.25B 2,063B P/E 2026 *
63.6x
P/E 2027 * 51.6x
Enterprise Value 12.05B 10.59B 9.89B 9.07B 16.98B 1,155B 17.4B 117B 45.85B 571B 45.25B 44.27B 1,975B EV / Sales 2026 *
7.58x
EV / Sales 2027 * 6.59x
Free-Float
97.1%
Yield 2026 *
-
Yield 2027 * -
1 day+0.04%
1 week+1.15%
Current month+1.39%
1 month+1.48%
3 months-1.44%
6 months-10.33%
Current year+2.97%
1 week 317.09
Extreme 317.09
321.4
1 month 314.98
Extreme 314.985
321.4
Current year 290
Extreme 290
362.41
1 year 221.26
Extreme 221.26
362.41
3 years 148
Extreme 148
362.41
5 years 114.86
Extreme 114.865
362.41
10 years 56.05
Extreme 56.05
362.41
Manager TitleAgeSince
Chief Executive Officer 64 2004-06-20
President 41 2025-08-31
Director of Finance/CFO 54 2019-12-01
Director TitleAgeSince
Chairman 64 2014-12-31
Chairman 64 2004-12-31
Director/Board Member 59 2015-03-31
Date Insider Type Main position Quantity % Market Cap.
5/19/26 Don

Chief Executive Officer

-77,000 0.1958%
4/2/26 Sell

Director

100 0.0003%
3/15/26 Tax

Chairperson

117 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+0.04%+1.15%+40.93%+3.92% 12.59B
-0.29%+3.54%+21.11%+20.93% 6.67B
-2.11%+6.62%+53.44%+24.13% 5.99B
+4.31%+12.68% - - 5.17B
+2.57%+3.91%-24.54%+23.49% 4.55B
+3.01%-0.57%-21.77%-18.07% 4.09B
-6.81%-2.38%+33.63%-54.38% 1.77B
+3.39%+3.39%-15.04%+221.05% 1.72B
+0.64%-1.74%+56.09%-8.49% 1.51B
+1.94%+0.96%-29.86%-52.19% 1.23B
Average +0.67%+2.37%+12.67%+17.82% 4.53B
Weighted average by Cap. +0.65%+3.33%+21.37%+14.29%

Financials

2026 *2027 *
Net sales 1.59B 1.4B 1.3B 1.2B 2.24B 152B 2.3B 15.47B 6.05B 75.39B 5.97B 5.84B 261B 1.8B 1.58B 1.48B 1.36B 2.54B 172B 2.6B 17.51B 6.85B 85.33B 6.76B 6.61B 295B
Net income 198M 174M 162M 149M 279M 18.93B 285M 1.92B 752M 9.37B 742M 726M 32.39B 245M 215M 201M 184M 345M 23.45B 353M 2.38B 931M 11.6B 919M 899M 40.11B
Net Debt -538M -473M -441M -405M -758M -51.52B -777M -5.23B -2.05B -25.49B -2.02B -1.98B -88.13B -729M -640M -598M -548M -1.03B -69.79B -1.05B -7.09B -2.77B -34.54B -2.74B -2.68B -119B
Logo Penumbra, Inc.
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada, Australia and Singapore, as well as through distributors in select international markets.
Employees
4,700
Date Price Change Volume
26-07-29 US$320.13 +0.04% 365,272
26-07-28 US$319.99 +0.16% 457,807
26-07-27 US$319.49 +0.24% 338,837
26-07-24 US$318.73 +0.26% 364,538
26-07-23 US$317.90 +0.44% 690,849
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
16
Last Close Price
320.13USD
Average target price
361.58USD
Spread / Average Target
+12.95%

Quarterly revenue - Rate of surprise